Biogen’s Aduhelm Brings Uncertainty and Concern Regarding Federal Budget

The FDA recently approved Biogen’s Aduhelm for use in patients with Alzheimer’s disease. However, its high price tag—$56,000—means that many patients won’t be able to afford it. In addition, should Medicare elect to cover the drug, its budget may need to expand considerably, leading to a substantial economic burden placed on taxpayers.

“Three members of the independent FDA panel that advised against approving the drug have resigned in protest, arguing that there is insufficient and conflicting evidence regarding its benefits and a risk of side effects. They say further trials are needed to answer those concerns. The Centers for Medicare & Medicaid Services ultimately will decide whether federal health programs will cover the treatment and under what circumstances, but they tend to follow the FDA’s lead.” Read more here.

(Source: Benjy Sarlin, NBC News, 6/20/21)